CONTEXT: Increased backing for the post-COVID era decentralised clinical trials. Can’t help thinking that this feels like a dot com bubble that will burst when the first major safety concerns pop-up from a decentralised trial, with cries of “what were we thinking?”
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 6
1. “Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide”
2. “With backing from Bayer, a London firm will pitch its ‘hospitals at home’ concept for decentralized trials”
3. “London-based Huma unveiled a $130 million Series C on Wednesday, which it will use to expand its digital platform in the US, Asia and the Middle East”
4. “” The company says its platform can double clinical capacity and reduce hospital readmissions by over a third, with patient adherence levels of over 90%”
5. “Hitachi Ventures led the round along with Leaps by Bayer, and new shareholders include Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, HAT Technology Innovation Fund, Nikesh Arora (former president of SoftBank) and Michael Diekmann (chairman of Allianz)”